Intracavernous self-injection of papaverine and verapamil: a clinical experience.
In the years 1992-1993 40 impotent men received treatment with a combination of papaverine and verapamil as intracavernous self-injection (ISPV). Patients' age was between 40 and 75 years. Average injection doses were 5 mg verapamil and 20 mg papaverine. Among those patients no priapism was encountered. Scarring was documented in one patient. Combination therapy is reliable, well accepted and applicable with minimum local risks in erectile dysfunction men.
Bolayir
K
K
Department of Urology, State Hospital North-Cyprus.
Gökşin
N
N
D000328:Adult; D000368:Aged; D002921:Cicatrix / Q000209:etiology; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006406:Hematoma / Q000209:etiology; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010409:Penile Diseases / Q000209:etiology; D010410:Penile Erection; D011317:Priapism / Q000209:etiology; D012646:Self Administration; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D014700:Verapamil; D010208:Papaverine